Gilead is all over the major news already and “U
Post# of 148301
Maybe all potential treatments will have a good day as result but I doubt it. I think we take a slight hit. The good news is that if it really does help mild patients and we can stop even a small percentage of cases from becoming severe that’s a good thing and it doesn’t at all diminish how great Leronlimab can still be. Just another hurdle.